Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebelimab combined with concurrent chemoradiotherapy for first-line limited-stage small cell lung cancer
ChiCTR2500095305Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab in small cell lung cancer (SCLC), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Progression-free survival. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2500095305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095305.